期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

伊曲康唑在恶性血液病系统性真菌感染治疗中的应用 被引量：5

下载PDF
导出
摘要 对50例恶性血液病合并系统性真菌感染的患者使用斯皮仁诺,剂量为200～400mg/d,用药天数为14d。结果:用斯皮仁诺治疗的临床总有效率为70.0%,不良反应发生率较低(为4.0%),患者免疫力低下、化疗、粒细胞减少及糖皮质激素、免疫抑制剂和抗生素的使用是其发病的主要危险因素。认为对恶性血液病患者系统性真菌感染要早期诊断并尽快足疗程应用斯皮仁诺,可取得较好疗效。
作者 周海侠 孙爱宁 吴德沛 陈苏宁 仇惠英 唐晓文 傅铮铮
机构地区 苏州大学附属第一医院
出处 《苏州大学学报（医学版）》 CAS 北大核心 2005年第3期478-480,共3页 Suzhou University Journal of Medical Science
关键词 系统性真菌感染 伊曲康唑 恶性血液病
分类号 R733.06 [医药卫生—肿瘤] R519.05 [医药卫生—内科学]
  • 相关文献

参考文献7

  • 1Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia [J]. American Journal of Hematology, 1998,58(2):105-109.
  • 2Lee WL, Yuan CC, Chao HT, et al. Vaginal obliteration after total body irradiation and chemotherapy as treatment for acute myeloid leukemia [J]. European Journal of Obstetrics, Gynecology & Reproductive Biology, 2000,90(1):77-79.
  • 3Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infaetions during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome[J].Cancer, 2003,97(2):450-456.
  • 4Auner HW, Sill H, Mulabecirovic A, et al.Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma[J]. Annals of Hematology, 2002,81(7):374-377.
  • 5汪复.重视和加强深部真菌感染的诊断与治疗[J].中国抗感染化疗杂志,2003,3(4):193-193. 被引量：25
  • 6邓国华,王爱霞.15例真菌败血症的回顾性研究[J].中华内科杂志,2001,40(9):594-596. 被引量：57
  • 7郝飞.伊曲康唑在系统性真菌感染防治中的价值[J].中华内科杂志,2003,42(11):814-816. 被引量：2

二级参考文献27

  • 1[1]Denning DW. Munoz P. Advances in invasive fungal infection and antifungal therapy: introduction[J]. Clin Microbiol Infect 2001,7:(suppl2) Ⅵ
  • 2[2]Pfaller MA, Diekema DJ, Messer SA, et al. Activities of fluconazole and voriconazole against 1586 recent clinical isolates of candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS global antifungal susceptibility program, 2001[J]. J Clin Microbiol, 2003, 41: 1440-1446
  • 3Louie A，Antimicrob Agents Chemother，1999年，43卷，2831页
  • 4Prentice HG, Caillot D, Dupont B, et al. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: meeting report. Acta Haematol, 1999, 101: 56-62.
  • 5Kapsi SG, Ayres JW. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm, 2001, 229: 193-203.
  • 6Barone JA , Moskovitz BL, Guarnieri J, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy, 1998, 18: 295-301.
  • 7Reynes J, Bazin C, Ajana F,et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother, 1997, 41: 2554-2558.
  • 8Groll AH, Wood L,Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother, 2002,46: 2554-2563.
  • 9Michallet M, Persat F, Kranzhofer N, et al. Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant, 1998, 21: 1239-1243.
  • 10Prentice AG, Warnock DW, Johnson SA, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother, 1994, 34: 247-252.

共引文献80

同被引文献38

引证文献5

二级引证文献8

苏州大学学报（医学版）
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部